|

A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)

RECRUITINGPhase 2Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Actively Recruiting
PhasePhase 2
SponsorSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Started2024-03-22
Est. completion2025-09-22
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06222671

Summary

This study will evaluate the effect and safety of 608 in patients with nr-axSpA.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Female and male patients at least 18 years of age at the time of screening.
2. Diagnosis of axial spondyloarthritis according to Ankylosing Spondylo Arthritis International Society (ASAS) axial spondyloarthritis criteria
3. Objective signs of inflammation (magnetic resonance imaging (MRI) or abnormal C-reactive protein)
4. Total back pain as measured by NRS ≥ 4 at baseline

Exclusion Criteria:

1. Patients with other uncontrolled active inflammatory diseases.
2. Clinical laboratory tests and other tests that reveal abnormalities with clinical significance
3. Patients who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening.
4. History of cancer.
5. Known or suspected history of immunosuppression.
6. Known with allergic or intolerant to mometasone furoate spray or 608/placebo.

Conditions2

ArthritisAxial Spondyloarthritis

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.